ETON
Income statement / Annual
Last year (2024), Eton Pharmaceuticals, Inc.'s total revenue was $39.01 M,
an increase of 23.29% from the previous year.
In 2024, Eton Pharmaceuticals, Inc.'s net income was -$3.82 M.
See Eton Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$39.01 M |
$31.64 M |
$21.25 M |
$21.83 M |
$39,000.00 |
$959,000.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$15.60 M
|
$10.58 M
|
$6.93 M
|
$2.62 M
|
$286,000.00
|
$453,000.00
|
$63,000.00
|
$13,000.00
|
| Gross Profit |
$23.41 M
|
$21.06 M
|
$14.32 M
|
$19.21 M
|
-$247,000.00
|
$506,000.00
|
-$63,000.00
|
-$13,000.00
|
| Gross Profit Ratio |
0.6
|
0.67
|
0.67
|
0.88
|
-6.33
|
0.53
|
0
|
0
|
| Research and Development Expenses |
$3.26 M
|
$3.32 M
|
$4.00 M
|
$6.24 M
|
$14.10 M
|
$11.56 M
|
$5.63 M
|
$3.93 M
|
| General & Administrative Expenses |
$22.75 M
|
$18.93 M
|
$18.58 M
|
$14.47 M
|
$12.76 M
|
$7.55 M
|
$4.69 M
|
$4.83 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.62 M
|
| Selling, General & Administrative Expenses |
$22.75 M
|
$18.93 M
|
$18.58 M
|
$14.47 M
|
$12.76 M
|
$7.55 M
|
$4.69 M
|
$3.21 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$26.01 M
|
$22.25 M
|
$22.58 M
|
$20.70 M
|
$26.86 M
|
$19.11 M
|
$10.32 M
|
$7.14 M
|
| Cost And Expenses |
$41.61 M
|
$32.83 M
|
$29.51 M
|
$23.33 M
|
$27.15 M
|
$19.56 M
|
$10.32 M
|
$7.15 M
|
| Interest Income |
$0.00
|
$0.00
|
$761,000.00
|
$1.01 M
|
$859,000.00
|
$281,000.00
|
$164,000.00
|
$52,500.00
|
| Interest Expense |
$0.00
|
$0.00
|
$955,000.00
|
$1.01 M
|
$889,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.15 M
|
$901,000.00
|
$1.77 M
|
$447,000.00
|
$651,000.00
|
$447,000.00
|
$63,000.00
|
$13,000.00
|
| EBITDA |
-$1.45 M |
-$291,000.00 |
-$6.49 M |
-$1.12 M |
-$26.46 M |
-$18.15 M |
-$10.26 M |
-$7.14 M |
| EBITDA Ratio |
-0.04
|
-0.01
|
-0.31
|
-0.05
|
-678.46
|
-18.93
|
0
|
0
|
| Operating Income Ratio |
-0.07
|
-0.04
|
-0.39
|
-0.07
|
-695.15
|
-19.4
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.21 M
|
$503,000.00
|
-$761,000.00
|
-$460,000.00
|
-$859,000.00
|
$281,000.00
|
-$2.42 M
|
-$6,000.00
|
| Income Before Tax |
-$3.81 M
|
-$689,000.00
|
-$9.02 M
|
-$1.96 M
|
-$27.97 M
|
-$18.32 M
|
-$12.74 M
|
-$7.16 M
|
| Income Before Tax Ratio |
-0.1
|
-0.02
|
-0.42
|
-0.09
|
-717.18
|
-19.1
|
0
|
0
|
| Income Tax Expense |
$15,000.00
|
$247,000.00
|
$761,000.00
|
$1.01 M
|
$859,000.00
|
-$281,000.00
|
-$2.58 M
|
$0.00
|
| Net Income |
-$3.82 M
|
-$936,000.00
|
-$9.78 M
|
-$2.96 M
|
-$28.83 M
|
-$18.04 M
|
-$12.74 M
|
-$7.16 M
|
| Net Income Ratio |
-0.1
|
-0.03
|
-0.46
|
-0.14
|
-739.21
|
-18.81
|
0
|
0
|
| EPS |
-0.15 |
-0.0365 |
-0.39 |
-0.12 |
-1.37 |
-1.02 |
-1.99 |
-0.41 |
| EPS Diluted |
-0.15 |
-0.0365 |
-0.39 |
-0.12 |
-1.37 |
-1.02 |
-1.99 |
-0.41 |
| Weighted Average Shares Out |
$25.90 M
|
$25.65 M
|
$25.15 M
|
$25.21 M
|
$21.01 M
|
$17.76 M
|
$6.42 M
|
$17.46 M
|
| Weighted Average Shares Out Diluted |
$25.90 M
|
$25.65 M
|
$25.15 M
|
$25.21 M
|
$21.01 M
|
$17.76 M
|
$6.42 M
|
$17.46 M
|
| Link |
|
|
|
|
|
|
|
|
